<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SALSALATE</span><br/>(sal'sal-ate)<br/><span class="topboxtradename">Artha-G, </span><span class="topboxtradename">Mono-Gesic, </span><span class="topboxtradename">Salflex, </span><span class="topboxtradename">Salsitab<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">salicylate</span>; <span class="classification">antipyretic</span><br/><b>Prototype: </b>Aspirin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 750 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Action similar to those of other salicylates. Clinical studies suggest that salsalate does not produce significant gastric
         irritation, and it has not been associated with reactions causing asthmatic attacks in susceptible individuals. Unlike aspirin,
         it does not appear to inhibit platelet aggregation. Salsalate lowers body temperature by causing vasodilation of peripheral
         vessels. Its antiinflammatory and analgesic activity may be mediated through inhibition of the prostaglandin synthetase enzyme
         complex.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Analgesic, antipyretic, antiinflammatory and antirheumatic effects.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic treatment, rheumatoid arthritis, osteoarthritis, and related rheumatic disorders.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to salicylates or <small>NSAID</small>s, especially patients with history of asthma, nasal polyposis, or chronic urticaria; chronic renal insufficiency; peptic
         ulcer; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Liver function impairment; pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 3253000 mg/d in divided doses (max: 4 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a full glass of water or food or milk to reduce GI adverse effects.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Nausea, dyspepsia, heartburn, vomiting, diarrhea, risk of GI bleed. <span class="typehead">Special Senses:</span> Tinnitus, hearing loss (reversible). <span class="typehead">Body as a Whole:</span> Vertigo, flushing, headache, confusion, hyperventilation, sweating. <span class="typehead">CNS:</span> Drowsiness. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-negative results for Clinistix; false positives for Clinitest.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Aminosalicylic acid</b> increases risk of salicylate toxicity. <b>Ammonium</b> <b>chloride</b> and other <span class="classification">acidifying agents</span> decrease renal elimination and increase risk of salicylate toxicity. <span class="classification">anticoagulants</span> increase risk of bleeding. <span class="classification">oral hypoglycemic agents</span> increase hypoglycemic activity with salsalate doses &gt;2 g/d. <span class="classification">carbonic anhydrase inhibitors</span> enhance salicylate toxicity. <span class="classification">corticosteroids</span> add to ulcerogenic effects. <b>Methotrexate</b> toxicity is increased. Low doses of salicylates may antagonize uricosuric effects of <b>probenecid</b> and <b>sulfinpyrazone.</b> <span class="typehead">Herbal:</span> <b>Feverfew,</b> <b>garlic,</b> <b>ginger,</b> <b>ginkgo</b> may increase bleeding potential. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from small intestine. <span class="typehead">Peak:</span> 1.54 h. <span class="typehead">Metabolism:</span> Hydrolyzed in liver, GI mucosa, plasma, whole blood, and other tissues. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Symptom relief is gradual (may require 34 d to establish steady-state salicylate level).</li>
<li>Monitor for adverse GI effects, especially in patient with a history of peptic ulcer disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not to take another salicylate (e.g., aspirin) while on salsalate therapy.</li>
<li>Monitor blood glucose for loss of glycemic control in diabetes; drug may induce hypoglycemia when used with sulfonylureas.</li>
<li>Report tinnitus, hearing loss, vertigo, rash, or nausea.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>